Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine

Clinical and Experimental Immunology

Volumn 129, Issue 1, 2002, Pages 99-106

  Shawler, D L ^a,d   Bartholomew, R M ^b   Garrett, M A ^a   Trauger, R J ^b   Dorigo, O ^a   Van Beveren, C ^a   Marchese, A ^b   Ferre, F ^b   Duffy, C ^b   Carlo, D J ^b   Sherman, L A ^c   Gold, D P ^a   Sobol, R E ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b Orchestra Therapeutics Inc   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d NovaRx Corporation   (United States)

Author keywords

Colon carcinoma; Gene therapy; Immunotherapy; Tumor vaccines

Indexed keywords

ALLOANTIGEN; ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; HLA A2 ANTIGEN; MUCIN 1; PROTEIN P53; TUMOR ANTIGEN;

ARTICLE; BLOOD; CANCER CELL; CELL ACTIVITY; CELL LINE; CELL STIMULATION; CELL STRAIN; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL;

ANTIGEN PRESENTATION; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; CELLS, CULTURED; COLONIC NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FIBROBLASTS; HLA-A2 ANTIGEN; HUMANS; ISOANTIGENS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0036379468     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01863.x     Document Type: Article

References (34)

1. Shawler DL, Fakhrai H, Van Beveren C et al. Gene therapy approaches to enhance antitumor immunity. Adv Pharmacol 1997; 40:309-37.
2. Fakhrai H, Shawler DL, Gjerset R et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 1995; 6:591-601.
3. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 1990; 60:387-403.
4. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-23.
5. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57:503-12.
6. Sobol RE, Shawler DL, Carson C et al. Interleukin-2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res 1999; 5:2359-65.
7. Darrow TL, Slingluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989; 142:3329-35.
8. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90.
9. Ras E, van der Burg SH, Zegveld ST et al. Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum Immunol 1997; 53:81-9.
10. Crowley NJ, Slingluff CL Jr, Darrow TL, Seigler HF. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res 1990; 50:492-8.
11. Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni-Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51:3164-70.
12. Shawler DL, McCallister TJ, Sobol RE, Dillman RO. Serologic and cellular assays to monitor therapy with murine monoclonal antibodies. J Clin Lab Anal 1987; 1:184-90.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
14. De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40:360-9.
15. Dillman RO, Johnson DE, Shawler DL. Immune interferon modulation of in vitro murine anti-human T cell monoclonal antibody-mediated cytotoxicity. J Immunol 1986; 136:728-31.
16. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science 1986; 233:532-4.
17. Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 1998; 71:204-10.
18. Fakhrai H, Dorigo O, Shawler DL et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996; 93:2909-14.
19. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342:705-8.
20. Rodrigues NR, Rowan A, Smith ME et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87:7555-9.
21. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92:11993-7.
22. Han JS, Nair PP. Flow cytometric identification of cell surface markers on cultured human colonic cell lines using monoclonal antibodies. Cancer 1995; 76:195-200.
23. Hanski C, Drechsler K, Hanisch FG et al. Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis (x) expression. Cancer Res 1993; 53:4082-8.
24. Tannapfel A, Kuhn R, Kessler H, Wittekind C. Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. Anal Cell Pathol 1996; 10:149-60.
25. Conry RM, Khazaeli MB, Saleh MN et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 1999; 5:2330-7.
26. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997; 57:4570-7.
27. MacCallum J, Bartlett JM, Thompson AM, Keen JC, Dixon JM, Miller WR. Expression of transforming growth factor beta mRNA isoforms in human breast cancer [see comments]. Br J Cancer 1994; 69:1006-9.
28. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 1993; 24:4-9.
29. Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, Greig R. Growth factor production by human colon carcinoma cell lines. Cancer Res 1989; 49:2898-904.
30. Mondino A, Jenkins MK. Surface proteins involved in T cell costimulation. J Leukoc Biol 1994; 55:805-15.
31. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11:211-6.
32. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259:368-70.
33. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993; 90:5687-90.
34. Chong H, Hutchinson G, Hart IR, Vile RG. Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 1996; 7:1771-9.